$CPMD

CANNAPHARMARX, INC.

CannaPharmaRx specializes in acquiring, developing and operating cannabis cultivation facilities in Canada. It produces and sells dried cannabis flower, packaged as dried flower and trim shake, and focuses on medical cannabis and craft products. Its principal business activities include cannabis cultivation, processing and distribution, conducted by its subsidiary, Alberta Ltd. CannaPharmaRx sells cannabis in Germany, Israel, Canada and Portugal. It operates an indoor farm in Cremona, Alberta, with six growing rooms currently in operation and a drying and packing room. The company holds Canadian cultivation, processing and sale licenses. It makes money by selling cannabis products, and its current European delivery process sends cannabis to a third-party intermediary for packaging to EU-GMP standards. CannaPharmaRx is headquartered in Mountain View County, Alberta, Canada.

0
0
1

No SEC Form 4 filings for $CPMD in the last 30 days.

See all $CPMD insider activity →
Med

CannaPharmaRx 3Q 2026: Revenue $137.71K, EPS ($0.00) — 10-Q Summary

CannaPharmaRx reported 3Q 2026 revenue of $137.71K, down 79% YoY, with net income of $645.42K, reversing a prior loss. Lower sales volumes, including no Cantek sales, drove revenue decline, while non-cash gains improved earnings. The company has $32,037 in cash and a $30.93M working-capital deficiency, with management expressing doubt about its ability to continue operations.

CPMD sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning CPMD (CANNAPHARMARX, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

What's driving CPMD

  • The filing highlights severe liquidity stress and collapsing sales, which typically pressures microcap cannabis equities and raises dilution or restructuring risk.

    tradingview.com · Nov 17, 2026

AlphAI scores every news story that mentions CPMD with an AI model for sentiment and relevance, and aggregates insider trades from CANNAPHARMARX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CPMD

Score

CannaPharmaRx 3Q 2026: Revenue $137.71K, EPS ($0.00) — 10-Q Summary

CannaPharmaRx reported 3Q 2026 revenue of $137.71K, down 79% YoY, with net income of $645.42K, reversing a prior loss. Lower sales volumes, including no Cantek sales, drove revenue decline, while non-cash gains improved earnings. The company has $32,037 in cash and a $30.93M working-capital deficiency, with management expressing doubt about its ability to continue operations.

Related tickers